Evidence map›Paper›PMID 30564290›Full record

ArticleMobile DNA2018

Properties of LINE-1 proteins and repeat element expression in the context of amyotrophic lateral sclerosis.

Gavin C Pereira, Laura Sanchez, Paul M Schaughency, Alejandro Rubio-Roldán, Jungbin A Choi, Evarist Planet, Ranjan Batra, Priscilla Turelli, Didier Trono, Lyle W Ostrow and 7 more

Open access · goldAbstract read
In one paragraph

Article in Mobile DNA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. LINE-1 Retrotransposons and Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Radiogenomics ofThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Gavin C Pereira1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
Laura Sanchez2GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Paul M Schaughency3Oncology Center-Cancer Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
Alejandro Rubio-Roldán2GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Jungbin A Choi1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
Evarist Planet4School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Ranjan Batra5Department of Neurosciences, School of Medicine, University of California at San Diego, San Diego, California USA.
Priscilla Turelli4School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Didier Trono4School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Lyle W Ostrow6Neuromuscular Division, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
John Ravits5Department of Neurosciences, School of Medicine, University of California at San Diego, San Diego, California USA.
Haig H Kazazian1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
Sarah J Wheelan3Oncology Center-Cancer Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.
Sara R Heras2GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
Jens Mayer8Department of Human Genetics, Medical Faculty, University of Saarland, Homburg/Saar, Germany.
Jose Luis García-Pérez2GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain.
John L Goodier1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA.ORCID 0000-0002-6168-5272
Johns Hopkins University · USÉcole Polytechnique Fédérale de Lausanne · CHPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESUniversity of San Diego · USSaarland University · DEUniversidad de Granada · ESWestern General Hospital · GB

Funding

TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 1985 to 2020
$25.6M
Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells-SupplementU54NS091046 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI FINKBEINER, STEVEN M, FRAENKEL, ERNEST · 2014 to 2020
$11.7M
Training CoreP50GM107632 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BOEKE, JEF D · 2013 to 2017
$10.0M
Retrotransposition in Health and DiseaseR01GM099875 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI KAZAZIAN, HAIG H. · 2012 to 2019
$4.0M
A role for endogenous retroelements in Aicardi-Goutieres SyndromeR21HD083915 · NICHD · JOHNS HOPKINS UNIVERSITY · PI GOODIER, JOHN LAWRENCE · 2016 to 2017
$449k
Exploring a role for LINE1 retrotransposons in neurodegenerative diseaseR03NS087290 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GOODIER, JOHN LAWRENCE · 2014 to 2015
$162k
NICHD NIH HHS R21 HD083915NIEHS NIH HHS P30 ES002109NIGMS NIH HHS P50 GM107632NIGMS NIH HHS R01 GM099875NINDS NIH HHS R03 NS087290NINDS NIH HHS U54 NS091046Wellcome Trust
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease involving loss of motor neurons and having no known cure and uncertain etiology. Several studies have drawn connections between altered retrotransposon expression and ALS. Certain features of the LINE-1 (L1) retrotransposon-encoded ORF1 protein (ORF1p) are analogous to those of neurodegeneration-associated RNA-binding proteins, including formation of cytoplasmic aggregates. In this study we explore these features and consider possible links between L1 expression and ALS.

resultsWe first considered factors that modulate aggregation and subcellular distribution of LINE-1 ORF1p, including nuclear localization. Changes to some ORF1p amino acid residues alter both retrotransposition efficiency and protein aggregation dynamics, and we found that one such polymorphism is present in endogenous L1s abundant in the human genome. We failed, however, to identify CRM1-mediated nuclear export signals in ORF1p nor strict involvement of cell cycle in endogenous ORF1p nuclear localization in human 2102Ep germline teratocarcinoma cells. Some proteins linked with ALS bind and colocalize with L1 ORF1p ribonucleoprotein particles in cytoplasmic RNA granules. Increased expression of several ALS-associated proteins, including TAR DNA Binding Protein (TDP-43), strongly limits cell culture retrotransposition, while some disease-related mutations modify these effects. Using quantitative reverse transcription PCR (RT-qPCR) of ALS tissues and reanalysis of publicly available RNA-Seq datasets, we asked if changes in expression of retrotransposons are associated with ALS. We found minimal altered expression in sporadic ALS tissues but confirmed a previous report of differential expression of many repeat subfamilies in

conclusionsHere we extended understanding of the subcellular localization dynamics of the aggregation-prone LINE-1 ORF1p RNA-binding protein. However, we failed to find compelling evidence for misregulation of LINE-1 retrotransposons in sporadic ALS nor a clear effect of ALS-associated TDP-43 protein on L1 expression. In sum, our study reveals that the interplay of active retrotransposons and the molecular features of ALS are more complex than anticipated. Thus, the potential consequences of altered retrotransposon activity for ALS and other neurodegenerative disorders are worthy of continued investigation.

Identifiers

PMID30564290
PMCPMC6295051
OpenAlexW2905289636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.